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Chronic hepatitis C is a major cause of chronic liver disease globally, and the natural history of progression may lead to cirrhosis
with liver failure, hepatocellular carcinoma, and premature liver-related death. Emerging data demonstrates that interferon-based
therapy, particularly among those achieving a sustained virologic response (SVR), is associated with long-term persistence of SVR,
improved ﬁbrosis and inﬂammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy. This
reduction in the rate of progression has also been demonstrated in patients with chronic hepatitis C and cirrhosis in some but
not all studies. The majority of these results are reported with standard interferon therapy, and long-term results of peginterferon
plus ribavirin therapy with a higher likelihood of SVR should have a yet greater impact on the population of treated patients.
The impact on slowing progression is greatest in patients with an SVR, less in relapsers, and equivocal in nonresponders. Thus,
the natural history of chronic hepatitis C after completion of antiviral therapy is favorable with achievement of an SVR, although
furtherdataareneededtodeterminethelikelyincrementalimpactofpeginterferonplusribavirin,latelong-termeﬀectsoftherapy,
and the beneﬁt of treatment in patients with advanced hepatic ﬁbrosis.
1.Introduction
Hepatitis C virus (HCV) is a leading cause of chronic liver
disease and a major public health problem, with 130 to
170 million people infected worldwide [1]. Chronic HCV
infection may result in serious sequelae, such as end-stage
cirrhosis, hepatocellular carcinoma (HCC), need for liver
transplantation,andprematuredeath[2].TreatmentofHCV
infection with interferon was ﬁrst used successfully in 1986
[3], and interferon in its pegylated formulation in combina-
tion with ribavirin is the preferred therapy for the treatment
of patients with acute or chronic HCV infection [4]. The
current treatment of chronic hepatitis C is peginterferon
alfa-2a or alfa-2b plus ribavirin, with approximately 55% to
65% of patients across all genotypes achieving a sustained
virologic response (SVR) [5–7]. However, only 42% to 52%
of patients with genotype 1 infection have an SVR after 48
weeks of combination therapy in pivotal trials [5–7]. SVR is
traditionally deﬁned as an undetectable serum HCV RNA 24
weeks after the discontinuation of therapy and is regarded as
a“ c u r e ”[ 4], although an undetectable HCV RNA 12 weeks
after completion of therapy appears to be equally as relevant
for prediction of an SVR in patients treated with peginter-
feron plus ribavirin [8]. The primary goal of treatment of
chronic hepatitis C is to prevent late liver-related morbidity
and mortality, and measurement of SVR is the short-term
surrogate used to predict the long-term eﬃcacy of antiviral
therapy. The purpose of this concise paper is to summarize
current knowledge on the impact of antiviral therapy on per-
sistence of SVR and long-term outcomes, including impact
on hepatic ﬁbrosis, incidence of HCC, and life expectancy.
These data provide a rationale for the early use of antiviral
therapy not only to achieve an SVR but also to favorably
impact the long-term prognosis of chronic hepatitis C.2 Hepatitis Research and Treatment
Table 1: Durability of undetectable serum HCV RNA after SVR.
Author, year of publication (reference) Patients no. Followup period years Detectable HCV RNA no. (%)
Marcellin et al. [9] 80 4 (mean) 3 (4)
Reichard et al. [10] 26 5.4 (mean) 2 (8)
McHutchison et al. [11] 395; 151 5 (mean) 10 (2.5%); 2 (1.3)
1
Veldt et al. [12] 286 Up to 4.9 12 (4)
Formann et al. [13] 187 2.4 (median) 0 (0)
Desmond et al. [14] 147 2.3 (mean) 1 (0.7)
Lindsay et al. [15] 366 4.8 (mean) 4 (1)
Maylin et al. [16] 344 3.3 (mean) 0 (0)
George et al. [17] 147 5.4 (median) 0 (0); 9 (6)
2
Kim et al. [18] 73 Not reported 8 (11); 1 (1.4)
3
Patients in the above studies who were followed after an SVR are heterogeneous and include those with all genotypes and various treatment regimens,
including interferon monotherapy, interferon plus ribavirin and peginterferon plus ribavirin, and various treatment durations for 24 or 48 weeks; patients
were generally na¨ ıve to prior therapy, but relapsers were included in some studies.
1395 patients with an SVR and participating in 4 studies were followed, including na¨ ıve and relapsed patients, and patients were treated with interferon
monotherapy or interferon plus ribavirin for 24 or 48 weeks; of these 395 patients, a subset of 151 patients were na¨ ıve and received interferon plus ribavirin
for 48 weeks.
2No patient had detectable HCV RNA using PCR (sensitivity = 29IU/mL); 9 patients had HCV RNA detectable by TMA (sensitivity = 5.3IU/mL) on one
sample (mean of 4 samples from the 9 patients), but all other samples of these 9 patients were negative by TMA.
3HCV RNA was detectable by qualitative PCR in 8 patients, but only one patient had persistent viremia.
2.SustainedVirologicalResponse Persists
Long Term
Theearlieststudydemonstratingthatasustainedresponseto
antiviral therapy was associated with long-term biochemical
and virological responses as well as histologic improvement
was reported by Marcellin and colleagues from France [9].
In this study of 80 patients who had a 6-month sustained
biochemical and virologic response, mean followup of
4 years showed that 93% of patients had a persistently
normal alanine aminotransferase (ALT) level, and 96% had
undetectable serum HCV RNA. A comparison of hepatic
histology before and 1 to 6.2 years after completion of
interferon therapy showed improvement in 94% of patients,
and HCV RNA was undetectable in the liver in 1 to 5
years after treatment in all 27 patients tested. In an analysis
of 4 large trials in which 395 patients were followed after
achieving an SVR with interferon alfa-2b with or without
ribavirin, the actuarial likelihood of maintaining response
after a mean 5-year followup was 99% ± 1%, with overall
10 patients (2.5%) developing detectable HCV RNA and all
within 2 years of followup [11]. Thus, this analysis of a large
study database conﬁrmed that late relapse is rare in patients
whoremainHCVRNAnegative24weeksaftercompletionof
interferon-based therapy. Multiple other studies [10, 12–18],
includingonesmallstudywitha10-yearmeanfollowup[19],
showed that SVR predicts a high likelihood of long-term
SVR (Table 1). One of these studies followed 344 patients
for a median duration of 3.3 years (range, 0.5 to 18 years)
after completion of interferon-based therapy with an SVR,
and showed that serum HCV RNA remained undetectable
in 1300 samples, indicating that none had a relapse with up
to 18 years of followup [16]. It is unclear if late detection
of serum HCV RNA after an SVR in a small number of
patients represents true relapse, especially if the detection
occurs only once or is intermittent and with use of a very
sensitive assay. Although additional followup studies may
provide further clariﬁcation of this distinction, an SVR
appears for now to be durable and an accurate reﬂection of a
cure.
3. NaturalHistoryof ChronicHepatitisC
The progression of HCV infection is relatively slow, and
the risk of developing cirrhosis ranges from 4%−25% in
infected persons over 20−30 years of followup [4, 26–28].
Older age at the time of HCV infection, male gender, obesity,
immunosuppression, and heavy alcohol intake are associated
with a more rapid progression rate [28–32]. The annual
rate of developing HCC in the presence of cirrhosis ranges
from 1%−3% in Western countries to 5%−7% in Japan [33–
38]. The higher proportion of elderly patients infected with
HCV in Japan may explain the higher incidence rate in this
country, since older age accelerates the development of HCC
[39]. Hepatic decompensation of cirrhosis occurs at a rate of
3% to 4% per year [33, 34].
4.AntiviralTherapyImprovesHepaticFibrosis
and Inﬂammation
Changes in histologic ﬁndings following a course of inter-
feron therapy have been studied extensively. Shiratori and
colleagues [40] analyzed paired liver biopsies of 593 patients;
487 received interferon monotherapy for no longer than 6
months and 106 were untreated. Fibrosis regressed at a rate
of 0.28 Metavir units per year in those who achieved an SVR.
A meta-analysis of data from 1,013 patients from 3 largeHepatitis Research and Treatment 3
randomized trials [41–43] demonstrated that peginterferon
treatment reduced inﬂammation and ﬁbrosis in patients
with an SVR or who relapsed, but not in nonresponders
[44]. This improvement was more prominent with use of
peginterferon rather than interferon. Signiﬁcant improve-
ment has also been shown after use of peginterferon and
ribavirin combination therapy, with achievement of SVR
[45]. Even in patients with advanced ﬁbrosis or cirrhosis,
inﬂammation and ﬁbrosis were improved with interferon
monotherapy, peginterferon monotherapy, or peginterferon
plus ribavirin combination therapy [44–46]. In a pooled set
of data from 3,010 na¨ ıve hepatitis C patients with pretreat-
ment and posttreatment biopsies form 4 randomized trials
of 10 diﬀerent regimens using combinations of standard
interferon alfa-2b, peginterferon alfa-2b and ribavirin, it
was shown that there was a 39% to 73% improvement in
necrosis and inﬂammation [45]. In addition, all regimens
signiﬁcantly reduced ﬁbrosis progression rates in compar-
ison to rates before treatment, with the best results noted
with peginterferon plus ribavirin. In particular, cirrhosis
was reversed in 49% of patients with baseline cirrhosis.
Six factors were associated with the absence of signiﬁcant
ﬁbrosis after treatment: baseline ﬁbrosis stage, SVR, age <40
years, body mass index <27kg/m2, no or minimal baseline
activity, and HCV RNA level <3.5 millioncopies/mL [45].
In contrast to the study of Camm` a et al. [44], the analysis
of Poynard and colleagues showed slowing of the natural
progression of ﬁbrosis in nonresponders, as well as those
with an SVR and relapsers [45]. A limitation of both of these
studies is the relatively short time between paired biopsies,
that is, before treatment and 24 week after completion of
therapy.
In summary, studies of antiviral therapy with inter-
feron monotherapy, peginterferon monotherapy, or pegin-
terferon plus ribavirin combination therapy demonstrate an
improvement in inﬂammation and ﬁbrosis in patients with
an SVR, to a lesser extent in relapsers, and uncertain beneﬁt
in nonresponders.
5. AntiviralTherapy Is Associatedwith
aReducedIncidenceofHepatocellular
Carcinoma
The Inhibition of Hepatocarcinogenesis by Interferon Ther-
apy (IHIT) Study Group in Japan has been studying the
development of HCC in approximately 3,000 Japanese
patients with chronic hepatitis C and has demonstrated that
interferon therapy reduces the risk of HCC by half including
down to one-ﬁfth in biochemical or virological responders,
compared with untreated patients [37]. The preventive eﬀect
of interferon on development of HCC was also reported
by Imai et al. [39], who conducted a retrospective study of
419 patients receiving interferon monotherapy for 6 months
and compared the incidence rate of HCC with untreated
controls. The relative risk (RR) for HCC was 0.06 (P = .007)
in patients with an SVR, and 0.51 (P = .15) in relapsers,
and 0.95 (P>. 2) in nonresponders, indicating that only
an SVR was associated with a reduced risk of HCC. In
contrast, another study demonstrated that the incidence of
HCC was decreased not only in patients with an SVR, but
also in relapsers when compared with nonresponders [47].
Compatible with the studies cited above, the IHIT Study
Group has also demonstrated reduced inﬂammation and
ﬁbrosis in patients with an SVR [40]. However, it should be
notedthatareductionintheriskofHCCdoesnotnecessarily
indicate improvement in overall survival, and interferon is
less eﬀective in patients with cirrhosis. In addition, cirrhotic
patients tend to be older, and liver-unrelated mortality may
be signiﬁcant and obscure any potential beneﬁt of interferon
therapy.
6. Life ExpectancyIs Prolonged with
Interferon-Based Therapy
It would be expected that long-term durability of an SVR,
improvement in ﬁbrosis and inﬂammation, and a reduced
incidence of HCC would translate into a prolonged life
expectancy. In fact, recent studies with suﬃciently long
followup are now reporting this ultimate end-point of
antiviral therapy [36, 48–50]. In a retrospective cohort
study of 7 university hospitals and 1 regional core hospital
in Japan, 2,889 patients with biopsies, including 2,430
patients receiving interferon and 459 untreated patients
were analyzed [49]. Compared with the general population,
overall mortality was high among untreated patients but
not among the treated patients. In the interferon-treated
patients,theriskofliver-relateddeathwasreducedcompared
with untreated patients, while the risk of liver-unrelated
death remained unchanged. In another study of 459 patients
followed for a mean of 8.2 years, multivariate regression
analysis revealed that interferon treatment decreased the risk
ratio for overall death and liver-related death, particularly
in patients with an SVR [48]. Once again, interferon
showed no association with liver-unrelated death. Another
retrospective cohort study of 2,954 patients, including 2,698
who were treated and 256 who were untreated, showed
similar results [50]. Over a mean 6-year followup, interferon
therapy improved survival in chronic hepatitis C patients
showing a biochemical as well as a virological response by
preventing liver-related deaths. Finally, a prospective cohort
6.8-year followup study of 345 patients with cirrhosis, of
whom 271 were treated and 74 not treated, showed that
interferon inhibited the development of HCC and also
improved survival [36]. In contrast to the above ﬁndings, an
Australian study demonstrated that IFN treatment reduced
liver complications, but the beneﬁcial eﬀect of achieving an
SVR was marginal (P<. 058) in a multivariate analysis
[51].
7. Impact of AntiviralTherapy in Patients with
ChronicHepatitisC andCirrhosis
What about the impact of antiviral therapy in patients
with chronic hepatitis C and cirrhosis? Shiratori et al. [36]
conducted a prospective study on 345 cirrhotic patients, of
whom 271 received interferon monotherapy for a median of4 Hepatitis Research and Treatment
6.5months,evaluatingthecumulativeincidenceofHCCand
survival relative to 74 untreated patients; SVR was attained
in 15% of these patients. In patients who achieved an SVR,
the age-adjusted hazard ratio (HR) for developing HCC
and death was signiﬁcantly reduced to 0.31 (P<. 001)
and 0.05 (P = .003), respectively, whereas the outcomes
for those who did not attain an SVR were not signiﬁcantly
diﬀerent from the control group. Bruno et al. [52]performed
a retrospective cohort study of 920 cirrhotic patients treated
with interferon monotherapy for 1 year, which resulted in an
SVR rate of 13.5%. Failure to achieve an SVR had a higher
risk of liver-related complications, HCC, and liver-related
mortality. Thirty-three percent of patients achieved an SVR
after peginterferon plus ribavirin combination therapy and
had better outcomes than those who did not attain an SVR
[53]. Multivariate analysis revealed that a failure to achieve
an SVR was associated with a higher risk of liver-related
complications, HCC, and liver-related mortality compared
to those who achieved an SVR.
However, several studies have demonstrated no bene-
ﬁcial eﬀect of IFN therapy on the prognosis of cirrhotic
patients [33, 54, 55]. A lower SVR rate (4%−9%) or shorter
followup period (median, 2.1 years) in these studies may
have underestimated the beneﬁt of interferon therapy. A
recently published meta-analysis demonstrated that antiviral
treatment was associated with a reduced risk of HCC
in patients who attained an SVR, compared with nonre-
sponders; the best outcomes were seen in patients treated
with ribavirin-based regimes, which conﬁrms the results of
other meta-analyses [56–58]. The attainment of SVR also
demonstrated prevention of the development of esophageal
varices [34].
T h e r eh a v eb e e nc a s er e p o r t s[ 59] and long-term fol-
lowup studies that have shown the development of HCC in
patients with advanced hepatic ﬁbrosis after the achievement
of an SVR [17, 36, 52, 55, 60]. In one followup study, the
two patients who developed HCC were diagnosed 5.8 and
7.3 years after having achieved an SVR. These observations
underscore the continued risk of HCC and need for ongoing
surveillance with imaging and alpha-fetoprotein testing in
patients with chronic hepatitis C and advanced hepatic
ﬁbrosis, even after an SVR.
In summary, multiple studies have shown that the
achievement of an SVR with antiviral therapy reduces, but
does not eliminate, the incidence of HCC and decreases
liver-related complications and liver-related mortality in
patients with chronic hepatitis C, and in some studies
also in cirrhotics. However, the eﬀect of antiviral therapy
is controversial in patients who were responders during
treatment and subsequently relapsed after treatment and
probably has limited beneﬁt in nonresponders.
8. Preventive Effect of Interferon on Recurrence
of Tumor after Treatment of HCC
To evaluate eﬀects of interferon treatment on HCC recur-
rence after resection of HCC, studies were performed
in which patients were randomized to receive interferon
treatment or to remain untreated [61, 62]. Patients in
the interferon-treated group received interferon alpha for
approximately 2 years, but only 2 patients (13%) achieved an
SVR.HCCrecurrencewasobservedin33%oftheinterferon-
treated group and in 80% of the control group. The
recurrence rate was signiﬁcantly lower and the cumulative
survival rate signiﬁcantly higher in the interferon group
than in the control group [61, 62]. In another randomized
controlled study, 74 patients with cirrhosis and low HCV
RNA loads were assigned to receive interferon for 1 year (n =
49) or to an untreated control group (n = 25) after complete
ablation of HCC by percutaneous ethanol injection therapy
[63]. SVR was achieved in 29% of patients. Interferon
treatment seemed to suppress the rate of a second or third
recurrence of HCC, but not a ﬁrst recurrence, and improve
thesurvivalrate.Severalstudies,includingonemeta-analysis
with one exception, indicate that the achievement of SVR
appears to prevent the recurrence of HCC [64–69]. However,
as virtually all of these studies were conducted in Japan, a
deﬁnitiveconclusionshouldawaitfurtherreportsfromother
regions of the world.
9. Impact of Maintenance Therapy on
Outcomes of ChronicHepatitis C with
Advanced Fibrosis
An earlier randomized controlled trial revealed that long-
term low-dose interferon treatment for patients who did
not obtain an SVR with previous standard interferon-based
therapy improved liver histology [20]( Table 2). In addition,
Nishiguchi et al. [70, 71] demonstrated that interferon
monotherapy for 12 to 24 weeks reduced the occurrence
of HCC and disease progression. Although these studies
included a small number of patients, the results encouraged
clinicians to perform large studies to conﬁrm the impact of
maintenance therapy for chronic hepatitis C with advanced
hepatic ﬁbrosis.
The HALT-C study enrolled 1,050 patients with bridging
ﬁbrosis or cirrhosis (deﬁned as an Ishak ﬁbrosis score of 3 or
more) who had not responded to a previous 6- or 12-month
course of therapy (lead-in phase) with peginterferon and
ribavirin [22, 72]. These patients were randomized to receive
either no therapy or peginterferon alfa-2a at a dose of 90μg
per week for 3.5 years. Although serum aminotransferase
levels, serum HCV RNA levels, and necroinﬂammatory
scores decreased signiﬁcantly with therapy, the rate of
primary outcome (death, HCC, hepatic decompensation, or
anincreaseintheIshakscoreof2ormorepoints)wassimilar
in the treatment and control groups (34.1% and 33.8%,
respectively), conﬁrming the results of a previously reported
randomized, controlled trial with a relatively small number
of patients [21].
In the HALT-C study, viral suppression of ≥4log 10
during the lead-in phase of therapy was associated with a
signiﬁcant reduction in clinical outcomes, although a sig-
niﬁcant diﬀerence was not observed between the treatment
and control groups [73]. Unexpectedly, viral suppression of
≥4log 10 during the phase of maintenance therapy did notHepatitis Research and Treatment 5
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result in an improvement in clinical outcomes. A decrease in
serum HCV RNA levels might improve the clinical outcome,
even if short-term and transient; thus viral suppression
during the lead-in phase may have obscured the beneﬁcial
eﬀect of maintenance therapy. The Nishiguchi study tested
interferon-na¨ ıve patients, which may have accentuated the
beneﬁcialeﬀectsofinterferon[70].Sixteenpercentoftreated
patients achieved an SVR in this study, which is unlikely in
studies enrolling previous nonresponders.
The results from two other large randomized trials are
currently unpublished. In the COPILOT study, patients with
an Ishak ﬁbrosis score of 3 or more who were nonresponders
to interferon therapy were randomized to receive either
peginterferon alfa-2b, at a dose of 0.5μg/kg weekly, or
colchicine. This maintenance therapy signiﬁcantly retarded
the development of varies and prevented variceal bleeding,
but did not aﬀect overall outcome [23, 24]. The EPIC3 study
also revealed that maintenance therapy was not superior
to control except in reducing clinical events in patients
with esophageal varices [25]. Finally, a recent meta-analysis
assessing the role of the maintenance interferon therapy in
nonresponders did not reduce the incidence of HCC (RR:
0.58; 95% CI: 0.33−1.03) [56].
In summary, there are insuﬃcient data to recommend
maintenance therapy for patients who did not respond
to previous interferon treatment. In the HALT-C study,
3.5 years of low-dose peginterferon improved histologic
necroinﬂammatory scores, but did not reduce the rate of
disease progression. Liver histology, especially ﬁbrosis, is
closely associated with prognosis [37, 48, 74, 75]. Therefore,
furtherfollowupofpatientsintheHALT-Ctrialmayconﬁrm
the inhibitory eﬀect of the maintenance therapy on the
progression of liver disease.
10. Conclusions
The long-term beneﬁt of antiviral therapy, including reduc-
tion in hepatic ﬁbrosis, lower incidence of HCC, and
prolonged life expectancy, appears to be limited primarily
to patients able to achieve an SVR. A recent systematic
review showed that health-related quality-of-life was also
improved and that antiviral treatment is reasonably cost
eﬀective in treatment-na¨ ıve patients as well as relapsers and
nonresponders[76].Therefore,cliniciansshouldaimtotreat
with antiviral therapy, with the goal of achieving an SVR
early in the natural history of chronic hepatitis C. Direct
acting antiviral (DAA) agents are expected to provide new
treatment options for management of chronic hepatitis C in
the near future. Telaprevir, an HCV NS3 protease inhibitor,
in combination with peginterferon and ribavirin, induced
SVR in approximately 70% of treatment-na¨ ıve genotype
1 patients and in 51% of patients who failed previous
peginterferon plus ribavirin therapy [77–79]. The increase in
SVR rate using DAA agents may provide a long-term beneﬁt
to a wider variety of patients, including nonresponders to
peginterferon and ribavirin therapy, and further improve
the long-term outcomes of therapy including slowed ﬁbrosis
progression, reduced incidence of HCC, and prolonged life
expectancy.
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